



Alkermes Announces Live Webcast of Investor Event Discussing Vivitrex Phase III Clinical Trial Results at the American Society of Addiction Medicine Annual Conference

April 22, 2004

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 22, 2004--Alkermes, Inc. (Nasdaq: ALKS) announced today that it will be webcasting its investor event live from the 35th Annual Conference of the American Society of Addiction Medicine (ASAM) on Friday, April 23, 2004 at 8:30am EDT from The Omni Shoreham Hotel in Washington, DC. Alkermes will host a breakfast with a presentation on Vivitrex(R), reporting six-month efficacy data in alcohol-dependent patients, based on the preliminary results from the Phase III clinical trial announced in December 2003. The presentation may be accessed under the investor relations tab at www.alkermes.com and will be archived for seven days.

Alkermes, Inc. is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our proprietary AIR(R) pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.

CONTACT: Alkermes, Inc.
Rebecca Peterson, 617-583-6378

SOURCE: Alkermes, Inc.